ASST Papa Giovanni XXIII | Ospedale di Bergamo - SC Malattie Endocrine-Diabetologia

Research site

(Unclaimed)

Location

PIAZZA OMS 1, BERGAMO, Bergamo, Italy

Site insights

Top conditions

Top treatments

Nivolumab

Atezolizumab

Finerenone

Odevixibat

Pembrolizumab

Gemcitabine

Carboplatin

Vericiguat

Avelumab

Ipilimumab

Parent organization

This site is a part of ASST Papa Giovanni XXIII

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

30 of 94 total trials

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (CADENCE)

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults wit...

Enrolling

Hypertension, Pulmonary

Drug: Placebo

Drug: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling

Biochemically Recurrent Prostate Cancer

Other: Placebo matching darolutamide

Drug: Darolutamide (BAY1841788, Nubeqa)

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve U...

Enrolling

Melanoma

Drug: ABP 206

Drug: Nivolumab

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPD...

Enrolling

Melanoma

Drug: EU-authorized Nivolumab

Drug: ABP 206

Locations recently updated

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling

Idiopathic Pulmonary Fibrosis

Drug: BMS-986278 Placebo

Drug: BMS-986278

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling

Progressive Pulmonary Fibrosis

Drug: BMS-986278 Placebo

Drug: BMS-986278

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...

Enrolling

Melanoma

Drug: nivolumab+rHuPH20

Drug: relatlimab+nivolumab

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Active, not recruiting

Chronic Kidney Disease

Type 2 Diabetes Mellitus

Drug: Finerenone (BAY94-8862 ) 20 mg

Drug: Finerenone Placebo

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling

High-risk Transient Ischemic Attack

Acute Non-cardioembolic Ischemic Stroke

Drug: Asundexian (BAY2433334)

Drug: Placebo

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progressi...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Paclitaxel

Drug: Nivolumab

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia (BOLD-EXT)

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia

Invitation-only

Biliary Atresia

Drug: Odevixibat

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma (TIDE-A)

This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order...

Enrolling

Renal Carcinoma Metastatic

Drug: Axitinib Oral Tablet

Drug: Avelumab

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)

The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participa...

Active, not recruiting

Melanoma

Other: Placebo

Biological: Nivolumab

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with...

Active, not recruiting

Biliary Atresia

Drug: Odevixibat

Drug: Placebo

Oral Administration of Actitan-F in Paediatric Diarrhoea

The goal of the study is to investigate the efficacy and safety of Lenodiar Pediatric (product under investigation) for the treatment of Chronic Diar...

Enrolling

Chronic Diarrhoea of Infants and/or Young Children

Device: Lenodiar Pediatric

Other: Placebo

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

POLAR is a phase III clinical trial, which will test the safety and efficacy of an investigational combination of drugs to learn whether the combinat...

Enrolling

Breast Cancer Recurrent

Drug: Standard endocrine therapy

Drug: Palbociclib 125mg

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in m...

Enrolling

Non-Small Cell Lung Cancer Metastatic

Gastric Cancer

Drug: MCLA-129

Drug: Osimertinib

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-...

Active, not recruiting

Melanoma

Other: Placebo

Biological: Pembrolizumab

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembro...

Active, not recruiting

Malignant Melanoma

Drug: Lenvatinib

Drug: Placebo for lenvatinib